FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2336851925> ?p ?o ?g. }

• W2336851925 endingPage "1004" @default.
• W2336851925 startingPage "997" @default.
• W2336851925 abstract "The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) treatment algorithm for knee osteoarthritis (OA) recommends symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) first line for the medium to long term management of OA, due to their ability to control pain, improve function, and delay joint structural changes. Among SYSADOAs, glucosamine is probably the most widely used intervention. In the present review of glucosamine for knee OA, we have investigated whether the evidence is greater for the patented crystalline glucosamine sulfate (pCGS) preparation (Rottapharm/Meda) than for other glucosamine formulations. Glucosamine is actually widely available in many forms, as the prescription-grade pCGS preparation, generic and over-the-counter formulations of glucosamine sulfate (GS) and food supplements containing glucosamine hydrochloride (GH), which vary substantially in molecular form, pharmaceutical formulation and dose regimens. Only pCGS is given as a highly bioavailable once daily dose (1500 mg) with a proven pharmacological effect. pCGS consistently reaches the plasma levels of around 10 μM required to inhibit interleukin-1 induced expression of genes involved in the pathophysiology of joint inflammation and tissue destruction, compared with sub-therapeutic levels achieved with GH. It is evident, from careful consideration of the evidence base, that only the pCGS formulation of glucosamine reliably provides an effect size on pain that is higher than that of paracetamol and equivalent to that provided by non-steroidal anti-inflammatory drugs. In comparison, the effect size on pain of non-crystalline GS preparations and GH from randomized controlled trials is repeatedly demonstrated to be zero. In addition, there is evidence that chronic administration of pCGS has disease-modifying effects, with a reduction in the need for total joint replacement surgery lasting for at least 5 years after treatment cessation. Consequently, the pCGS preparation (Rottapharm/Meda) is the logical choice, with demonstrated medium-term control of pain and lasting impact on disease progression." @default.
• W2336851925 created "2016-06-24" @default.
• W2336851925 creator A5012926852 @default.
• W2336851925 creator A5014231492 @default.
• W2336851925 creator A5020061892 @default.
• W2336851925 creator A5026952227 @default.
• W2336851925 creator A5028502093 @default.
• W2336851925 creator A5082275964 @default.
• W2336851925 date "2016-02-26" @default.
• W2336851925 modified "2023-10-18" @default.
• W2336851925 title "A review of glucosamine for knee osteoarthritis: why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes" @default.
• W2336851925 cites W1950509440 @default.
• W2336851925 cites W1975603714 @default.
• W2336851925 cites W1980120754 @default.
• W2336851925 cites W1980359398 @default.
• W2336851925 cites W1986215651 @default.
• W2336851925 cites W1986876909 @default.
• W2336851925 cites W2002218955 @default.
• W2336851925 cites W2003513603 @default.
• W2336851925 cites W2012909933 @default.
• W2336851925 cites W2013977767 @default.
• W2336851925 cites W2019749134 @default.
• W2336851925 cites W2025797414 @default.
• W2336851925 cites W2026609781 @default.
• W2336851925 cites W2027020554 @default.
• W2336851925 cites W2032776363 @default.
• W2336851925 cites W2034030689 @default.
• W2336851925 cites W2035833931 @default.
• W2336851925 cites W2036491373 @default.
• W2336851925 cites W2040717958 @default.
• W2336851925 cites W2042319337 @default.
• W2336851925 cites W2048803404 @default.
• W2336851925 cites W2054994464 @default.
• W2336851925 cites W2058505385 @default.
• W2336851925 cites W2067585939 @default.
• W2336851925 cites W2069148797 @default.
• W2336851925 cites W2074339153 @default.
• W2336851925 cites W2083078813 @default.
• W2336851925 cites W2087492003 @default.
• W2336851925 cites W2092422416 @default.
• W2336851925 cites W2106059946 @default.
• W2336851925 cites W2113079259 @default.
• W2336851925 cites W2113853411 @default.
• W2336851925 cites W2114426847 @default.
• W2336851925 cites W2115805053 @default.
• W2336851925 cites W2130513475 @default.
• W2336851925 cites W2130761860 @default.
• W2336851925 cites W2153862724 @default.
• W2336851925 cites W2160331588 @default.
• W2336851925 cites W2161736885 @default.
• W2336851925 cites W2164287243 @default.
• W2336851925 cites W2169805813 @default.
• W2336851925 cites W2170132723 @default.
• W2336851925 cites W2181799658 @default.
• W2336851925 doi "https://doi.org/10.1185/03007995.2016.1154521" @default.
• W2336851925 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26881468" @default.
• W2336851925 hasPublicationYear "2016" @default.
• W2336851925 type Work @default.
• W2336851925 sameAs 2336851925 @default.
• W2336851925 citedByCount "40" @default.
• W2336851925 countsByYear W23368519252016 @default.
• W2336851925 countsByYear W23368519252017 @default.
• W2336851925 countsByYear W23368519252018 @default.
• W2336851925 countsByYear W23368519252019 @default.
• W2336851925 countsByYear W23368519252020 @default.
• W2336851925 countsByYear W23368519252021 @default.
• W2336851925 countsByYear W23368519252022 @default.
• W2336851925 countsByYear W23368519252023 @default.
• W2336851925 crossrefType "journal-article" @default.
• W2336851925 hasAuthorship W2336851925A5012926852 @default.
• W2336851925 hasAuthorship W2336851925A5014231492 @default.
• W2336851925 hasAuthorship W2336851925A5020061892 @default.
• W2336851925 hasAuthorship W2336851925A5026952227 @default.
• W2336851925 hasAuthorship W2336851925A5028502093 @default.
• W2336851925 hasAuthorship W2336851925A5082275964 @default.
• W2336851925 hasBestOaLocation W23368519251 @default.
• W2336851925 hasConcept C126322002 @default.
• W2336851925 hasConcept C142724271 @default.
• W2336851925 hasConcept C185592680 @default.
• W2336851925 hasConcept C204787440 @default.
• W2336851925 hasConcept C2776164576 @default.
• W2336851925 hasConcept C2776237595 @default.
• W2336851925 hasConcept C2778125326 @default.
• W2336851925 hasConcept C55493867 @default.
• W2336851925 hasConcept C71924100 @default.
• W2336851925 hasConcept C98274493 @default.
• W2336851925 hasConceptScore W2336851925C126322002 @default.
• W2336851925 hasConceptScore W2336851925C142724271 @default.
• W2336851925 hasConceptScore W2336851925C185592680 @default.
• W2336851925 hasConceptScore W2336851925C204787440 @default.
• W2336851925 hasConceptScore W2336851925C2776164576 @default.
• W2336851925 hasConceptScore W2336851925C2776237595 @default.
• W2336851925 hasConceptScore W2336851925C2778125326 @default.
• W2336851925 hasConceptScore W2336851925C55493867 @default.
• W2336851925 hasConceptScore W2336851925C71924100 @default.
• W2336851925 hasConceptScore W2336851925C98274493 @default.
• W2336851925 hasIssue "6" @default.
• W2336851925 hasLocation W23368519251 @default.

• next